Simple blood test could spot hidden myeloma years early
NCT ID NCT07684274
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests a new blood test that looks for DNA fragments in the blood (called cfDNA) to detect multiple myeloma and its early forms (MGUS and smoldering myeloma) in people over 40. The test uses machine learning to tell the difference between healthy individuals and those with the disease. If it works, it could lead to a simple, non-invasive way to catch myeloma early, when treatment is more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blood test (liquid biopsy cfDNA fragmentomics)
- What this could lead to
- If successful, this could enable a simple blood test to catch multiple myeloma at an early, more treatable stage.
- What could go wrong
- This is an early-stage study with 290 participants, so the model may not be accurate enough for widespread use. It is also tailored to the Chinese population and may not apply to other groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MGUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a closer look at bone complications in multiple myeloma improve rehabilitation?
- Gene-Guided Chemo-Free strategy targets AL amyloidosis
- New PET tracer aims to reveal hidden myeloma spots
- Personalized immunotherapy strategies aim to improve outcomes for frail myeloma patients
- AI-Powered diet advice could help cancer patients eat better during treatment
- New scan technique could sharpen cancer imaging